Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by CAMP4 Therapeutics
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
October 14, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
September 10, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
September 08, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 to Participate in Upcoming Investor Conferences
September 01, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 13, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
August 04, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
July 27, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 19, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 21, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
May 14, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
May 07, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
April 28, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Appoints Michael MacLean to its Board of Directors
March 24, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 to Participate in Upcoming Investor Conferences
March 06, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
March 05, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
December 18, 2025
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
December 18, 2025
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2025
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2025
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
November 06, 2025
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
October 01, 2025
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
September 10, 2025
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 14, 2025
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American
May 16, 2025
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
May 13, 2025
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
April 28, 2025
From
CAMP4 Therapeutics
Via
GlobeNewswire
Tickers
CAMP
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
